Hemant Misra
Corporate Officer/Principal at Prolong Pharmaceuticals LLC
Profile
Hemant Misra is currently the Vice President of Clinical Development at Prolong Pharmaceuticals LLC since 2011.
Prior to this, he worked as the Director of Clinical Drug and Corporate Development at rEVO Biologics, Inc. and as the Head of Development and Quality System at ActiveCyte, Inc.
Hemant Misra active positions
| Companies | Position | Start |
|---|---|---|
Prolong Pharmaceuticals LLC
 Prolong Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Prolong Pharmaceuticals LLC develops and manufactures biopharmaceutical products to treat anemias, cancers and their debilitating comorbidities. The firm focuses on sickle cell anemia, diabetic ischemia, and several trauma indications. Its products include SANGUINATE, an oxygen transfer agent to treat anemia and protein therapeutics. The company was founded by Abraham Abuchowski in 2002 and is headquartered in South Plainfield, NJ. | Corporate Officer/Principal | 26/01/2011 |
Former positions of Hemant Misra
| Companies | Position | End |
|---|---|---|
| ActiveCyte, Inc. | Corporate Officer/Principal | - |
| REVO BIOLOGICS INC | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Prolong Pharmaceuticals LLC
Prolong Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Prolong Pharmaceuticals LLC develops and manufactures biopharmaceutical products to treat anemias, cancers and their debilitating comorbidities. The firm focuses on sickle cell anemia, diabetic ischemia, and several trauma indications. Its products include SANGUINATE, an oxygen transfer agent to treat anemia and protein therapeutics. The company was founded by Abraham Abuchowski in 2002 and is headquartered in South Plainfield, NJ. | Health Technology |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
| ActiveCyte, Inc. |
- Stock Market
- Insiders
- Hemant Misra